European Partnership for Personalised Medicine (EP PerMed)
Open
25 Nov 2025 / 02 Nov 2026
Deadline
20th January 2027 (13:00 local Irish time)
Duration
Up to 3 years
- Call opens4th November 2026
- Contact detailseu-cofund@researchireland.ie
Important Dates
Summary
The European Partnership for Personalised Medicine (EP PerMed) supported by the European Union under Horizon Europe, is now launching its fourth Joint Transnational Call for Proposals (2027) for Cell and Gene Therapy for Personalised Medicine (CGT4PM2027). The call fosters collaboration between academic, clinical/public health and private research teams and involves a two-stage process.
The European Partnership for Personalised Medicine (EP PerMed) supported by the European Union under Horizon Europe, provides a transnational platform to support research and innovation in personalised medicine, and to accelerate implementation into healthcare systems for the benefit of patients and society as defined by the Partnership’s Strategic Research & Innovation Agenda.
EP PerMed is now launching its fourth Joint Transnational Call for Proposals (2027) for Cell and Gene Therapy for Personalised Medicine (CGT4PM2027). In total, 39 funding organisations across 28 countries are participating in this call with an available budget of ~€38 million.
The EP PerMed funding organisations have agreed to fund multinational, innovative research projects in personalised medicine (PM), which should bring together academic, clinical/public health and private research teams, thus enhancing the competitiveness in Europe and beyond in this field.
The call will follow a two-stage process, i.e. a pre-proposal phase followed by an invited full-proposal phase.
The 2027 Joint Transnational Call will fund research projects in human health on cell and gene therapy (CGT) for personalised medicine (PM). The EP PerMed overall aims to:
- Foster interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as preclinical and clinical research, bioinformatics/health informatics/data research, ethics, social sciences, law makers, etc.;
- Encourage cross-sectorial collaborations between academic researchers and the private sector (e.g. small and medium enterprises (SMEs), large enterprises), healthcare providers, patient/citizen organisations, etc.
Proposals must focus on the development and validation of an innovative and novel CGT for PM. For this call, CGT are considered innovative and novel when they offer clear therapeutic advantages over the standard of care, such as improved efficacy, enhanced safety, longer-lasting effects, or the ability to address previously untreatable conditions.
Research projects in all disease areas are encouraged. At least one of the following approaches must be employed:
- Somatic cell therapeutics (e.g., stem cells, organoids or cells of the immune system);
- Gene therapeutics in the form of gene substitution, addition or suppression therapies using viral and non-viral vectors or genome editing;
- Combined cell and gene therapeutics in the form of genetically modified cells;
- Novel biological products such as mRNA, other nucleic acid-based methods and extracellular vesicles as a vehicle for gene-based therapeutic procedures.
The research projects have to use physiologically relevant preclinical models (e.g., human cell cultures, organoids, organs-on-chips, animal models). Furthermore, they have to show solid preliminary data (e.g., defined vector or cell system, existing preclinical model) and have to describe a credible pathway towards clinical application.
Accompanying the above research fields, proposals may include:
- Diagnostic approaches provided there is a clear link to personalised CGT;
- Development of novel manufacturing or delivery methods provided they incorporate a personalised CGT backbone;
- Preclinical in vitro/in vivo characterisation assays for novel and personalised CGT.
Research projects in all disease areas are encouraged.
Please review the Call Text for full details on the scope of the call, including research areas that are out of scope, and aspects to be considered during the preparation of proposals.
Awarded projects will have a duration of up to 36 months. For applicants based in Ireland, Research Ireland will provide the following funding for projects:
- Up to a maximum of €330,000 direct costs* per award for Irish applicants as Partner on transnational proposals.
- Up to a maximum of €405,000 direct costs* per award for Irish applicants as Coordinator on transnational proposals.
*The maximum total award, including overhead contribution, will be €430,000, for a partner and €530,000 for applicants who take on the role of coordinator.
Only an academic partner or coordinator based in an eligible Irish Host Research body may apply for Research Ireland funding.
The Irish-based applicant requesting Research Ireland funding must:
- hold a PhD or equivalent qualification for at least 3 years by the pre-proposal deadline. The official date is defined as the day, month and year that the degree was conferred i.e., the month and year printed on the official PhD certificate.
AND
- be a member of the academic staff of an eligible Research Body (permanent or with an active contract that covers the period of the grant)
OR
- be a contract researcher with a contract that covers the period of the grant, who is recognised by the eligible Research Body as an independent investigator and will have an independent office and research space for which he/she will be fully responsible for at least the duration of the Research Ireland grant
OR
- be an individual who will be recognised by the eligible Research Body upon receipt of the grant as an academic staff or as a contract researcher as defined above. The applicant does not necessarily need to be employed by the Research Body at the time of the application submission.
AND
- be an author on at least three international peer-reviewed articles. Only original research publications, and not review articles or other secondary research literature, are acceptable.
In addition:
- Research Ireland will only accept one application per applicant.
All requested costs must be comprehensively justified. Please include detailed descriptions and cost itemisation in the proposal.
- Salary-related costs for research personnel. Please use current Research Ireland Team Member Salary Scales. The Irish partner cannot request their own salary or buy-out.
- Equipment costs up to a maximum value of €10K
- Travel costs with consideration for Research Ireland’s Guidance for Sustainable Travel Policy
- Direct running costs (materials and consumables)
- Dissemination and knowledge exchange costs
- Subcontracting costs may be considered an eligible budget category however strong justification for subcontracting must be provided and pre-approved directly with Research Ireland in advance of pre-proposal submission.
Unless otherwise stated, all rules regarding listed eligible costs apply as defined within Research Ireland’s grant budget policy. Please refer to this policy closely in the development of the budget request.
Research Ireland will not provide a contribution towards the salary of the applicant, international co-applicants or collaborators.
All additional ineligible costs apply as described in Research Ireland’s grant budget policy.
Please give a brief notification of your intent to submit a pre-proposal through email to eu-cofund@researchireland.ie before the submission deadline. Within the notification, please include the following information:
- List of project partners
- Irish Host institution*
- Total budget requested from Research Ireland**
- Whether you intend to apply as a coordinating or non-coordinating partner
- Whether you hold a permanent contract or an active contract that covers the grant period.
*Please note it is also the responsibility of the applicant to notify the Research Office of their Host Institution of their intention to submit a pre-proposal.
**Applicants must submit a separate budget template to Research Ireland alongside their notification of intent, which should include a brief breakdown and justification for each cost category.
The completed pre-proposal must be submitted directly on the EP PerMed submission platform.
- Official Ep PerMed Call website: EP PerMed Joint Transnational Call (JTC) 2027 – European Partnership for Personalised Medicine – EP PerMed
- Partnership Website: https://www.eppermed.eu/
- Strategic Research & Innovation Agenda for Personalised Medicine: https://www.eppermed.eu/publications-resources/ep-permed-publications/strategic-research-innovation-agenda-for-personalised-medicine/
EP PerMed is organising a Call Information Day on 3 December 2026 from 15:00 to 17:00 CET for the EP PerMed JTC2027 ‘Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)’
Click the link below for further information and to register:
Downloads
Co-Funded By
This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101137129.







